Physician profile
Sandra Abramson
NPI 1275538282
$6,969.53
in general payments reported to CMS, 2019-2025
9 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,867 · 2020: $80.94 · 2021: $19.55 · 2022: $645 · 2023: $689 · 2024: $2,548 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,310 · Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,310.38 |
| Food and Beverage | $1,046.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $4,204.41 | 2019-2024 | Evoque |
| Medtronic Vascular, INC. | $1,210.76 | 2019 | |
| Medtronic, INC. | $683.24 | 2022-2024 | Apollotm |
| Boston Scientific Corporation | $408.89 | 2019-2025 | Farapulse, Watchman Flx, Watchman Access System |
| Abbott Laboratories | $266.58 | 2019-2025 | Mitraclip |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $77.54 | 2024 | Lifevest |
| Lantheus Medical Imaging, INC. | $64.83 | 2019-2024 | Definity |
| Ge Healthcare | $39.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Abramson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.